Side effects of the Covishield vaccine: an ex-ICMR scientist claims that only 7 out of 10 lakh people may be at risk
A very small percentage of people may be at risk for extremely rare side effects from the Covishield vaccine, such as thrombosis with thrombocytopenia syndrome (TTS), according to former ICMR scientist Dr. Raman Gangakhedkar.
According to Dr. Raman Gangakhedkar, a former scientist at the Indian Council of Medical Research (ICMR), very few people may be at risk from the COVID-19 vaccine, also known as Covishield.
According to Gangakhedkar, News18, only seven to eight people out of ten lakh recipients of the Covishield vaccine are at risk of developing Thrombosis Thrombocytopenia Syndrome (TTS), a rare side effect.
“The first dose carries the highest risk. According to News18, the epidemiologist stated, “It decreases with the second dose and is lowest with the third.”
The scientist added that any negative effects would probably show up in the first two to three months. He continued by saying that the associated risk is negligible considering the benefits of this vaccine for millions of recipients.
AstraZeneca, the multinational pharmaceutical company that collaborated with the University of Oxford to develop the COVID-19 vaccine, recently acknowledged in UK court filings that the vaccine may result in Thrombosis with Thrombocytopenia Syndrome (TTS), an uncommon side effect.
